TP53 and in situ carcinoma: Thus, the 4R- Pal-p53p has potential as a therapy for: (1) mutant p53 cancers, (2) over-expressed WT p53 cancers and (3) treatment for cells with premalignant, mutant p53 status or carcinoma in situ.